Table 2.
Comparing model performance for clinically meaningful cognitive outcomes by addition of plasma amyloid-beta and other biomarkers to model with demographic factors (Cox proportional hazard regression)
| Harrell’s C index | p | ||
|---|---|---|---|
| Incident dementia | |||
| Demographic factors: age, sex, education, MAPT group, BMI | 0.8019 | Ref | |
| Plus Aβ42/40 | 0.8075 | 0.684 | Ref |
| Plus Aβ42/40, TNFR1, IL6, MCP11 | 0.8163 | 0.508 | 0.568 |
| Worsening of CDR status | |||
| Demographic factors: age, sex, education, MAPT group, BMI, initial CDR score | 0.8155 | Ref | |
| Plus Aβ42/40 | 0.8169 | 0.726 | Ref |
| Plus Aβ42/40, GDF15, TNFR1, IL61 | 0.8197 | 0.416 | 0.338 |
| Plus Aβ42/40, NfL, GDF15, TNFR1, IL61 | 0.8197 | 0.420 | 0.342 |
Aβ, amyloid-beta; BMI, body mass index; CDR, clinical dementia rating; GDF15, growth differentiation factor 15; IL6, interleukin 6; MAPT, Multidomain Alzheimer Preventive Trial; MCP1, monocyte chemoattractant protein 1; NfL, neurofilament light chain; TNFR1, tumor necrosis factor receptor type 1
1The multi-biomarker combination which showed the highest Harrell’s C index compared to other biomarker models; Harrell’s C indices of models with other biomarker combinations are provided in the supplementary materials